193 related articles for article (PubMed ID: 36454709)
41. Association of cortical microstructure with amyloid-β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults.
Rodriguez-Vieitez E; Montal V; Sepulcre J; Lois C; Hanseeuw B; Vilaplana E; Schultz AP; Properzi MJ; Scott MR; Amariglio R; Papp KV; Marshall GA; Fortea J; Johnson KA; Sperling RA; Vannini P
Mol Psychiatry; 2021 Dec; 26(12):7813-7822. PubMed ID: 34588623
[TBL] [Abstract][Full Text] [Related]
42. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
[TBL] [Abstract][Full Text] [Related]
43. Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration.
Blazhenets G; Frings L; Ma Y; Sörensen A; Eidelberg D; Wiltfang J; Meyer PT;
Neurology; 2021 Mar; 96(9):e1358-e1368. PubMed ID: 33408150
[TBL] [Abstract][Full Text] [Related]
44. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
45. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
46. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
47. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A
J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991
[TBL] [Abstract][Full Text] [Related]
48. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
[TBL] [Abstract][Full Text] [Related]
49. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
Liu E; Wang D; Sperling R; Salloway S; Fox NC; Blennow K; Scheltens P; Schmidt ME; Streffer J; Novak G; Einstein S; Booth K; Ketter N; Brashear HR;
Neurology; 2018 Mar; 90(10):e877-e886. PubMed ID: 29429971
[TBL] [Abstract][Full Text] [Related]
50. The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey.
Caprioglio C; Garibotto V; Jessen F; Frölich L; Allali G; Assal F; Frisoni GB; Altomare D;
J Alzheimers Dis; 2022; 89(2):535-551. PubMed ID: 35912743
[TBL] [Abstract][Full Text] [Related]
51. High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations.
Sturchio A; Dwivedi AK; Malm T; Wood MJA; Cilia R; Sharma JS; Hill EJ; Schneider LS; Graff-Radford NR; Mori H; Nübling G; El Andaloussi S; Svenningsson P; Ezzat K; Espay AJ;
J Alzheimers Dis; 2022; 90(1):333-348. PubMed ID: 36120786
[TBL] [Abstract][Full Text] [Related]
52. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
53. Plasma ATN(I) classification and precision pharmacology in Alzheimer's disease.
Imbimbo BP; Watling M; Imbimbo C; Nisticò R
Alzheimers Dement; 2023 Oct; 19(10):4729-4734. PubMed ID: 37079778
[TBL] [Abstract][Full Text] [Related]
54. A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease.
Geerts H; Walker M; Rose R; Bergeler S; van der Graaf PH; Schuck E; Koyama A; Yasuda S; Hussein Z; Reyderman L; Swanson C; Cabal A
CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):444-461. PubMed ID: 36632701
[TBL] [Abstract][Full Text] [Related]
55. Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.
Russu A; Samtani MN; Xu S; Adedokun OJ; Lu M; Ito K; Corrigan B; Raje S; Liu E; Brashear HR; Styren S; Hu C
J Alzheimers Dis; 2016 May; 53(2):535-46. PubMed ID: 27163805
[TBL] [Abstract][Full Text] [Related]
56. Gray to white matter signal ratio as a novel biomarker of neurodegeneration in Alzheimer's disease.
Putcha D; Katsumi Y; Brickhouse M; Flaherty R; Salat DH; Touroutoglou A; Dickerson BC
Neuroimage Clin; 2023; 37():103303. PubMed ID: 36586361
[TBL] [Abstract][Full Text] [Related]
57. Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer's disease continuum: biological and methodological perspectives from disease heterogeneity.
Mohanty R; Ferreira D; Nordberg A; Westman E;
Alzheimers Res Ther; 2023 Feb; 15(1):37. PubMed ID: 36814346
[TBL] [Abstract][Full Text] [Related]
58. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Shcherbinin S; Evans CD; Lu M; Andersen SW; Pontecorvo MJ; Willis BA; Gueorguieva I; Hauck PM; Brooks DA; Mintun MA; Sims JR
JAMA Neurol; 2022 Oct; 79(10):1015-1024. PubMed ID: 36094645
[TBL] [Abstract][Full Text] [Related]
59. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
Klein G; Delmar P; Voyle N; Rehal S; Hofmann C; Abi-Saab D; Andjelkovic M; Ristic S; Wang G; Bateman R; Kerchner GA; Baudler M; Fontoura P; Doody R
Alzheimers Res Ther; 2019 Dec; 11(1):101. PubMed ID: 31831056
[TBL] [Abstract][Full Text] [Related]
60. Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers.
Baldeiras I; Silva-Spínola A; Lima M; Leitão MJ; Durães J; Vieira D; Tábuas-Pereira M; Cruz VT; Rocha R; Alves L; Machado Á; Milheiro M; Santiago B; Santana I
J Alzheimers Dis; 2022; 90(1):419-432. PubMed ID: 36120784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
